Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Gut Retrieve available abstracts of 177 articles: HTML format

Single Articles

April 2024
1. SUISSA S, Hernaez R
   Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?
   Gut. 2024;73:721-724.
   PubMed    
   
   
   
2. LIU B, Peng G, Yin Y, Shen C, et al
   Genetic evidence for repurposing of glucagon-like peptide-1 receptor agonists to prevent chronic liver diseases.
   Gut. 2024;73:879-882.
   PubMed    
   
   
   
3. WESTER A, Shang Y, Toresson Grip E, Matthews AA, et al
   Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.
   Gut. 2024;73:835-843.
   PubMed     Abstract available
   
   
   
4. ARMANDI A, Sanavia T, Younes R, Caviglia GP, et al
   Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
   Gut. 2024;73:825-834.
   PubMed     Abstract available
   
   
   March 2024
5. TREBICKA J, Hernaez R, Shawcross DL, Gerbes AL, et al
   Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
   Gut. 2024 Mar 25:gutjnl-2023-330584. doi: 10.1136/gutjnl-2023-330584.
   PubMed     Abstract available
   
   
   
6. HILDT E, Hu J
   New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release.
   Gut. 2024;73:566-567.
   PubMed    
   
   
   
7. TARGHER G, Byrne CD, Tilg H
   MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
   Gut. 2024;73:691-702.
   PubMed     Abstract available
   
   
   February 2024
8. LEE HH, Lee HA, Kim EJ, Kim HY, et al
   Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
   Gut. 2024;73:533-540.
   PubMed     Abstract available
   
   
   
9. CUBERO FJ, Sarobe P, Tiegs G
   Advancing with cancer immunotherapeutics: CD29(+) regulatory T cell antagonism.
   Gut. 2024;73:391-392.
   PubMed    
   
   
   
10. GREEN BL, Myojin Y, Ma C, Ruf B, et al
    Immunosuppressive CD29(+) Treg accumulation in the liver in mice on checkpoint inhibitor therapy.
    Gut. 2024;73:509-520.
    PubMed     Abstract available
    
    
    
11. HUNTER H, Johnston AJ, Said W, Wong NA, et al
    Colonic spider naevi in a middle-aged man.
    Gut. 2024;73:441-520.
    PubMed    
    
    
    
12. QIAN Z, Liang J, Huang R, Song W, et al
    HBV integrations reshaping genomic structures promote hepatocellular carcinoma.
    Gut. 2024 Feb 23:gutjnl-2023-330414. doi: 10.1136/gutjnl-2023-330414.
    PubMed     Abstract available
    
    
    
13. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    PubMed     Abstract available
    
    
    
14. KEATING CR, Calvisi DF, Qiu W
    High-fat diet-induced AKT-palmitoylation in hepatocellular carcinoma: a breakthrough mechanistic investigation.
    Gut. 2024 Feb 9:gutjnl-2023-331857. doi: 10.1136/gutjnl-2023-331857.
    PubMed    
    
    
    January 2024
15. HE T, Zhang D
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
    PubMed    
    
    
    
16. BARCENA-VARELA M, Berraondo P
    Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma.
    Gut. 2024 Jan 9:gutjnl-2023-331647. doi: 10.1136/gutjnl-2023-331647.
    PubMed    
    
    
    
17. 
    Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
    Gut. 2024;73:e3.
    PubMed    
    
    
    
18. KONG M, Zhou J, Kang A, Kuai Y, et al
    Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
    Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
    PubMed     Abstract available
    
    
    December 2023
19. YANG TC, Chen WC, Hou MC, Chen PH, et al
    Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial.
    Gut. 2023 Dec 14:gutjnl-2023-330419. doi: 10.1136/gutjnl-2023-330419.
    PubMed     Abstract available
    
    
    
20. CAI N, Cheng K, Ma Y, Liu S, et al
    Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.
    Gut. 2023 Dec 13:gutjnl-2023-331342. doi: 10.1136/gutjnl-2023-331342.
    PubMed     Abstract available
    
    
    
21. HEINEN N, Khanal R, Westhoven S, Klohn M, et al
    Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses.
    Gut. 2023 Dec 12:gutjnl-2023-330961. doi: 10.1136/gutjnl-2023-330961.
    PubMed    
    
    
    
22. YU X, Pfefferkorn M, van Bommel F, Zhang X, et al
    Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity.
    Gut. 2023 Dec 11:gutjnl-2023-331217. doi: 10.1136/gutjnl-2023-331217.
    PubMed    
    
    
    
23. CHOUIK Y, Levrero M
    Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
    Gut. 2023;73:10-11.
    PubMed    
    
    
    November 2023
24. LI R, Liu X, Huang X, Zhang D, et al
    Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
    Gut. 2023 Nov 30:gutjnl-2023-330243. doi: 10.1136/gutjnl-2023-330243.
    PubMed     Abstract available
    
    
    
25. ZHANG X, Yip TC, Wong GL, Leow WX, et al
    Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
    Gut. 2023;72:2364-2371.
    PubMed     Abstract available
    
    
    
26. RODERBURG C, Kostev K, Mertens A, Luedde T, et al
    Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer.
    Gut. 2023;72:2383-2384.
    PubMed    
    
    
    
27. EN LI CHO E, Ang CZ, Quek J, Fu CE, et al
    Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    Gut. 2023;72:2138-2148.
    PubMed     Abstract available
    
    
    
28. 
    Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023;72:e4.
    PubMed    
    
    
    October 2023
29. BRENNAN PN, Zelber-Sagi S, Allen AM, Dillon JF, et al
    Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
    Gut. 2023 Oct 28:gutjnl-2023-330771. doi: 10.1136/gutjnl-2023-330771.
    PubMed    
    
    
    
30. ARECHEDERRA M, Casadei Gardini A, Raggi C
    More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
    Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
    PubMed    
    
    
    
31. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
    Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
    Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
    PubMed     Abstract available
    
    
    
32. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
    Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
    PubMed     Abstract available
    
    
    
33. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed     Abstract available
    
    
    
34. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    PubMed    
    
    
    
35. CIOCAN D, Turpin W
    New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
    Gut. 2023;72:1812-1814.
    PubMed    
    
    
    
36. AVILA MA
    MicroRNA-223: a key regulator of liver tumour microenvironment.
    Gut. 2023;72:1811-1812.
    PubMed    
    
    
    September 2023
37. MANTOVANI A, Tilg H, Targher G
    FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials.
    Gut. 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
    PubMed    
    
    
    
38. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
    Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
    PubMed     Abstract available
    
    
    
39. RAMADORI P, Gallage S, Heikenwalder MF
    Unique tumour microenvironment: when ferroptosis activation boosts ICI of liver cancer.
    Gut. 2023;72:1639-1641.
    PubMed    
    
    
    
40. LUXENBURGER H, Thimme R
    SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease.
    Gut. 2023;72:1783-1794.
    PubMed     Abstract available
    
    
    
41. CONCHE C, Finkelmeier F, Pesic M, Nicolas AM, et al
    Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.
    Gut. 2023;72:1774-1782.
    PubMed     Abstract available
    
    
    August 2023
42. FAN Z, Jin M, Zhang L, Wang N, et al
    From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.
    Gut. 2023 Aug 7:gutjnl-2023-330461. doi: 10.1136/gutjnl-2023-330461.
    PubMed     Abstract available
    
    
    
43. MARJOT T, Tomlinson JW, Hodson L, Ray DW, et al
    Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD.
    Gut. 2023;72:1607-1619.
    PubMed     Abstract available
    
    
    
44. GRETEN TF
    'Invisible' immune checkpoint molecule causing resistance to anti-PD1 therapy in HCC.
    Gut. 2023;72:1440-1441.
    PubMed    
    
    
    July 2023
45. ZHAO L, Wu Q, Li Q, Chen A, et al
    TIPSS plus extrahepatic collateral embolisation may decrease variceal rebleeding and post-TIPSS hepatic encephalopathy.
    Gut. 2023 Jul 31:gutjnl-2023-330255. doi: 10.1136/gutjnl-2023-330255.
    PubMed    
    
    
    
46. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    PubMed    
    
    
    
47. WANG X, Huang H, Sze KM, Wang J, et al
    S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos.
    Gut. 2023;72:1370-1384.
    PubMed     Abstract available
    
    
    
48. MANTOVANI A, Csermely A, Tilg H, Byrne CD, et al
    Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
    Gut. 2023;72:1433-1436.
    PubMed    
    
    
    
49. BYRNE CD, Targher G
    Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people?
    Gut. 2023;72:1238-1239.
    PubMed    
    
    
    June 2023
50. POTENZA A, Balestrieri C, Spiga M, Albarello L, et al
    Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
    Gut. 2023 Jun 30:gutjnl-2022-328042. doi: 10.1136/gutjnl-2022-328042.
    PubMed     Abstract available
    
    
    
51. WITTKOP L, Boettler T
    More than shots in the dark: driving vaccine efficacy in cirrhosis.
    Gut. 2023 Jun 7:gutjnl-2023-329867. doi: 10.1136/gutjnl-2023-329867.
    PubMed    
    
    
    
52. FISCHER A, Ozdirik B, Geisel D, Malinka T, et al
    Gastric variceal bleeding in a patient with alcohol abuse: business as usual?
    Gut. 2023;72:1038-1114.
    PubMed    
    
    
    May 2023
53. ZHANG Q, Ye M, Lin C, Hu M, et al
    Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.
    Gut. 2023;72:996-1006.
    PubMed     Abstract available
    
    
    April 2023
54. LEWINSKA M, Karhus ML, Ellegaard AG, Romero-Gomez M, et al
    Serum lipidome unravels a diagnostic potential in bile acid diarrhoea.
    Gut. 2023 Apr 18:gutjnl-2022-329213. doi: 10.1136/gutjnl-2022-329213.
    PubMed     Abstract available
    
    
    
55. XIONG Z, Chan SL, Zhou J, Vong JSL, et al
    Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
    Gut. 2023 Apr 5:gutjnl-2022-328364. doi: 10.1136/gutjnl-2022-328364.
    PubMed     Abstract available
    
    
    March 2023
56. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    PubMed     Abstract available
    
    
    
57. CAMILLERI M, El-Omar EM
    Ten reasons gastroenterologists and hepatologists should be treating obesity.
    Gut. 2023 Mar 21:gutjnl-2023-329639. doi: 10.1136/gutjnl-2023-329639.
    PubMed    
    
    
    
58. LOOMBA R, Huang DQ, Sanyal AJ, Anstee QM, et al
    Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
    Gut. 2023;72:581-589.
    PubMed     Abstract available
    
    
    
59. SIMON TG, Roelstraete B, Alkhouri N, Hagstrom H, et al
    Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.
    Gut. 2023;72:573-580.
    PubMed     Abstract available
    
    
    
60. WANG S, Feng R, Wang SS, Liu H, et al
    FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression.
    Gut. 2023;72:549-559.
    PubMed     Abstract available
    
    
    February 2023
61. WEISS E, de la Pena-Ramirez C, Aguilar F, Lozano JJ, et al
    Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023 Feb 14:gutjnl-2022-328708. doi: 10.1136/gutjnl-2022-328708.
    PubMed     Abstract available
    
    
    
62. KANE SV, Reau N
    Clinical advances: pregnancy in gastroenterologic and hepatic conditions.
    Gut. 2023 Feb 9:gutjnl-2022-328893. doi: 10.1136/gutjnl-2022-328893.
    PubMed     Abstract available
    
    
    January 2023
63. HENDRIKX T, Lang S, Rajcic D, Wang Y, et al
    Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice.
    Gut. 2023 Jan 23:gutjnl-2022-328265. doi: 10.1136/gutjnl-2022-328265.
    PubMed     Abstract available
    
    
    
64. RAVAIOLI F, Dajti E, Mantovani A, Newsome PN, et al
    Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Gut. 2023 Jan 4:gutjnl-2022-328689. doi: 10.1136/gutjnl-2022-328689.
    PubMed     Abstract available
    
    
    
65. CHEN S, Huang C, Liao G, Sun H, et al
    Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.
    Gut. 2023 Jan 3:gutjnl-2022-328428. doi: 10.1136/gutjnl-2022-328428.
    PubMed     Abstract available
    
    
    
66. FU Y, Mackowiak B, Feng D, Lu H, et al
    MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
    Gut. 2023 Jan 2:gutjnl-2022-327924. doi: 10.1136/gutjnl-2022-327924.
    PubMed     Abstract available
    
    
    
67. ITZEL T, Falconer T, Daza J, Roig A, et al
    Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease.
    Gut. 2023;72:208-209.
    PubMed    
    
    
    
68. MONTIRONI C, Castet F, Haber PK, Pinyol R, et al
    Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
    Gut. 2023;72:129-140.
    PubMed     Abstract available
    
    
    
69. HERNAEZ R, Peck-Radosavljevic M
    MAFLD, HCC and the dilemma of (changing) terminology in liver diseases.
    Gut. 2023;72:9-11.
    PubMed    
    
    
    December 2022
70. LATIF MU, Schmidt GE, Mercan S, Rahman R, et al
    NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
    Gut. 2022;71:2561-2573.
    PubMed     Abstract available
    
    
    
71. RAO J, Wang H, Ni M, Wang Z, et al
    FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2.
    Gut. 2022;71:2539-2550.
    PubMed     Abstract available
    
    
    November 2022
72. TAN Z, Chiu MS, Yang X, Yue M, et al
    Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
    Gut. 2022 Nov 30:gutjnl-2022-327133. doi: 10.1136/gutjnl-2022-327133.
    PubMed     Abstract available
    
    
    
73. BAJAJ JS, Pena-Rodriguez M, La Reau A, Phillips W, et al
    Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis.
    Gut. 2022 Nov 7. pii: gutjnl-2022-328403. doi: 10.1136/gutjnl-2022-328403.
    PubMed     Abstract available
    
    
    
74. THEVENOT T, Desmarets M, Weil D, Di Martino V, et al
    Diameter of the shunt: the missing link in the appraisal of pTIPS in patients with cirrhosis with previous hepatic encephalopathy.
    Gut. 2022 Nov 3. pii: gutjnl-2022-328761. doi: 10.1136/gutjnl-2022-328761.
    PubMed    
    
    
    
75. DUFOUR JF, Marjot T, Becchetti C, Tilg H, et al
    COVID-19 and liver disease.
    Gut. 2022;71:2350-2362.
    PubMed     Abstract available
    
    
    
76. KASPER P, Lang S, Demir M, Steffen HM, et al
    Optimising the management of cardiovascular comorbidities in NAFLD patients: it's time to (re-) act!
    Gut. 2022;71:2365-2366.
    PubMed    
    
    
    September 2022
77. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    PubMed    
    
    
    
78. RUDLER M, Hernandez-Gea V, Procopet BD, Giraldez A, et al
    Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding.
    Gut. 2022 Sep 9. pii: gutjnl-2022-326975. doi: 10.1136/gutjnl-2022-326975.
    PubMed     Abstract available
    
    
    
79. LI X, Pan J, Liu T, Yin W, et al
    Novel TCF21(high) pericyte subpopulation promotes colorectal cancer metastasis by remodelling perivascular matrix.
    Gut. 2022 Sep 7:gutjnl-2022-327913. doi: 10.1136/gutjnl-2022-327913.
    PubMed     Abstract available
    
    
    
80. ZHAO Y, Yeo YH, Samaan J, Lv F, et al
    Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19.
    Gut. 2022 Sep 5. pii: gutjnl-2022-328188. doi: 10.1136/gutjnl-2022-328188.
    PubMed    
    
    
    
81. JOHN BV, Bastaich DR, Ferreira RD, Doshi A, et al
    COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis.
    Gut. 2022 Sep 5:gutjnl-2022-327799. doi: 10.1136/gutjnl-2022-327799.
    PubMed    
    
    
    
82. BYRNE CD, Targher G
    Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed.
    Gut. 2022;71:1695-1696.
    PubMed    
    
    
    
83. SIMON TG, Roelstraete B, Hagstrom H, Sundstrom J, et al
    Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Gut. 2022;71:1867-1875.
    PubMed     Abstract available
    
    
    August 2022
84. 
    Correction: Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2022;71:e9.
    PubMed    
    
    
    
85. LIU N, Wang X, Steer CJ, Song G, et al
    MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells.
    Gut. 2022;71:1642-1655.
    PubMed     Abstract available
    
    
    
86. ZHOU L, Yu KH, Wong TL, Zhang Z, et al
    Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression.
    Gut. 2022;71:1656-1668.
    PubMed     Abstract available
    
    
    
87. REVIA S, Seretny A, Wendler L, Banito A, et al
    Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
    Gut. 2022;71:1613-1628.
    PubMed     Abstract available
    
    
    
88. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.
    PubMed    
    
    
    July 2022
89. MONIN MB, Baier L, Berger M, Gorny JG, et al
    SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
    Gut. 2022 Jul 26. pii: gutjnl-2022-328169. doi: 10.1136/gutjnl-2022-328169.
    PubMed    
    
    
    
90. ANGELINI G, Panunzi S, Castagneto-Gissey L, Pellicano F, et al
    Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Gut. 2022 Jul 12. pii: gutjnl-2022-327498. doi: 10.1136/gutjnl-2022-327498.
    PubMed     Abstract available
    
    
    
91. BUCH S, Innes H, Lutz PL, Nischalke HD, et al
    Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
    Gut. 2022 Jul 4. pii: gutjnl-2022-327196. doi: 10.1136/gutjnl-2022-327196.
    PubMed     Abstract available
    
    
    
92. GRACIA-SANCHO J, Dufour JF
    NTCP: a pharmacological target for multiple liver conditions.
    Gut. 2022;71:1248-1250.
    PubMed    
    
    
    
93. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.
    PubMed    
    
    
    
94. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    PubMed     Abstract available
    
    
    June 2022
95. MORITA S, Duda DG
    Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
    Gut. 2022 Jun 30. pii: gutjnl-2022-327782. doi: 10.1136/gutjnl-2022-327782.
    PubMed    
    
    
    
96. BEA S, Jeong HE, Park S, Yu OHY, et al
    Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
    Gut. 2022 Jun 20. pii: gutjnl-2022-327504. doi: 10.1136/gutjnl-2022-327504.
    PubMed    
    
    
    
97. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed     Abstract available
    
    
    
98. MITHIEUX G
    Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327790. doi: 10.1136/gutjnl-2022-327790.
    PubMed    
    
    
    
99. SULLIVAN KM, Jiang X, Guha P, Lausted C, et al
    Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.
    Gut. 2022 Jun 15. pii: gutjnl-2021-325808. doi: 10.1136/gutjnl-2021-325808.
    PubMed     Abstract available
    
    
    
100. UCHE-ANYA E, Anyane-Yeboa A, Berzin TM, Ghassemi M, et al
     Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity.
     Gut. 2022 Jun 10. pii: gutjnl-2021-326271. doi: 10.1136/gutjnl-2021-326271.
     PubMed     Abstract available
     
     
     
101. MAJUMDAR A, Tsochatzis EA
     Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
     Gut. 2022;71:1236-1237.
     PubMed    
     
     
     May 2022
102. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
     Defining the key intrahepatic gene networks in HCV infection driven by sex.
     Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
     PubMed     Abstract available
     
     
     
103. DHAR A, Haboubi HN, Attwood SE, Auth MKH, et al
     British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.
     Gut. 2022 May 23. pii: gutjnl-2022-327326. doi: 10.1136/gutjnl-2022-327326.
     PubMed     Abstract available
     
     
     
104. MARTIN-SERRANO MA, Kepecs B, Torres-Martin M, Bramel ER, et al
     Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
     Gut. 2022 May 18. pii: gutjnl-2021-326514. doi: 10.1136/gutjnl-2021-326514.
     PubMed     Abstract available
     
     
     
105. GONZALEZ-RELLAN MJ, Novoa E, da Silva Lima N, Rodriguez A, et al
     Hepatic p63 regulates glucose metabolism by repressing SIRT1.
     Gut. 2022 May 17. pii: gutjnl-2021-326620. doi: 10.1136/gutjnl-2021-326620.
     PubMed     Abstract available
     
     
     
106. RIVOLTINI L, Bhoori S, Camisaschi C, Bergamaschi L, et al
     Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.
     Gut. 2022 May 4. pii: gutjnl-2021-326869. doi: 10.1136/gutjnl-2021-326869.
     PubMed    
     
     
     
107. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
     Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
     Gut. 2022;71:1006-1019.
     PubMed     Abstract available
     
     
     
108. TAMAKI N, Munaganuru N, Jung J, Yonan AQ, et al
     Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
     Gut. 2022;71:983-990.
     PubMed     Abstract available
     
     
     April 2022
109. HERNAEZ R, Avila MA
     Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
     Gut. 2022 Apr 26. pii: gutjnl-2022-327132. doi: 10.1136/gutjnl-2022-327132.
     PubMed    
     
     
     
110. ZHAO Y, Ren X, Lu J, He M, et al
     Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
     Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.
     PubMed    
     
     
     
111. HOHMANN N, Schroder F, Moreira B, Teng H, et al
     Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
     Gut. 2022;71:842-844.
     PubMed    
     
     
     
112. SMATI S, Polizzi A, Fougerat A, Ellero-Simatos S, et al
     Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target.
     Gut. 2022;71:807-821.
     PubMed     Abstract available
     
     
     
113. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
     Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
     Gut. 2022;71:778-788.
     PubMed     Abstract available
     
     
     March 2022
114. ZHANG C, Li J, Cheng Y, Meng F, et al
     Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients.
     Gut. 2022 Mar 31. pii: gutjnl-2021-325915. doi: 10.1136/gutjnl-2021-325915.
     PubMed     Abstract available
     
     
     
115. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
     Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
     Gut. 2022;71:657-658.
     PubMed    
     
     
     
116. HADERER M, Neubert P, Rinner E, Scholtis A, et al
     Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
     Gut. 2022;71:580-592.
     PubMed     Abstract available
     
     
     
117. RHA MS, Han JW, Koh JY, Lee HS, et al
     Impaired antibacterial response of liver sinusoidal Vgamma9(+)Vdelta2(+) T cells in patients with chronic liver disease.
     Gut. 2022;71:605-615.
     PubMed     Abstract available
     
     
     February 2022
118. LU LG, Zhou ZL, Wang XY, Liu BY, et al
     PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
     Gut. 2022 Feb 16. pii: gutjnl-2021-326350. doi: 10.1136/gutjnl-2021-326350.
     PubMed     Abstract available
     
     
     
119. SUN S, Yang Q, Zhou Q, Cao W, et al
     Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study.
     Gut. 2022;71:443-445.
     PubMed    
     
     
     
120. CAO Z, Xie Q
     Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
     Gut. 2022;71:445-446.
     PubMed    
     
     
     
121. FRANCQUE S, Wong VW
     NAFLD in lean individuals: not a benign disease.
     Gut. 2022;71:234-236.
     PubMed    
     
     
     
122. YOUNES R, Govaere O, Petta S, Miele L, et al
     Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
     Gut. 2022;71:382-390.
     PubMed     Abstract available
     
     
     
123. TREBICKA J, Gu W, de Ledinghen V, Aube C, et al
     Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease.
     Gut. 2022;71:402-414.
     PubMed     Abstract available
     
     
     January 2022
124. TIAN S, Chu Y, Hu J, Ding X, et al
     Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT.
     Gut. 2022 Jan 27. pii: gutjnl-2021-325137. doi: 10.1136/gutjnl-2021-325137.
     PubMed     Abstract available
     
     
     
125. SONDERGAARD JN, Sommerauer C, Atanasoai I, Hinte LC, et al
     CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism.
     Gut. 2022 Jan 12. pii: gutjnl-2021-325109. doi: 10.1136/gutjnl-2021-325109.
     PubMed     Abstract available
     
     
     
126. BELLOMO G, Rainer C, Quaranta V, Astuti Y, et al
     Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis.
     Gut. 2022 Jan 12. pii: gutjnl-2021-325272. doi: 10.1136/gutjnl-2021-325272.
     PubMed     Abstract available
     
     
     
127. JI F, Zhang J, Liu N, Gu Y, et al
     Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression.
     Gut. 2022 Jan 7. pii: gutjnl-2021-326050. doi: 10.1136/gutjnl-2021-326050.
     PubMed     Abstract available
     
     
     
128. SCHULZ M, Trebicka J
     Acute-on-chronic liver failure: a global disease.
     Gut. 2022;71:5-6.
     PubMed    
     
     
     
129. MEZZANO G, Juanola A, Cardenas A, Mezey E, et al
     Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
     Gut. 2022;71:148-155.
     PubMed     Abstract available
     
     
     
130. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
     Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
     Gut. 2022;71:156-162.
     PubMed     Abstract available
     
     
     December 2021
131. VITALE A, Svegliati-Baroni G, Ortolani A, Cucco M, et al
     Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
     Gut. 2021 Dec 21. pii: gutjnl-2021-324915. doi: 10.1136/gutjnl-2021-324915.
     PubMed     Abstract available
     
     
     
132. HUNG CT, Su TH, Chen YT, Wu YF, et al
     Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
     Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
     PubMed     Abstract available
     
     
     
133. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
     Large volume paracentesis: to do or where to do?
     Gut. 2021;70:2401-2402.
     PubMed    
     
     
     
134. BANG JY, Ward TJ, Guirguis S, Krall K, et al
     Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.
     Gut. 2021;70:2224-2226.
     PubMed    
     
     
     
135. ARNORIAGA-RODRIGUEZ M, Mayneris-Perxachs J, Contreras-Rodriguez O, Burokas A, et al
     Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways.
     Gut. 2021;70:2283-2296.
     PubMed     Abstract available
     
     
     
136. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
     RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
     Gut. 2021;70:2359-2372.
     PubMed     Abstract available
     
     
     
137. CARGILL Z, Cargill T, Lei B, Bekkali N, et al
     Uphill or downhill bleeding?
     Gut. 2021;70:2282-2348.
     PubMed    
     
     
     November 2021
138. LIU DS, Frampton AE
     Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma.
     Gut. 2021 Nov 19. pii: gutjnl-2021-325798. doi: 10.1136/gutjnl-2021-325798.
     PubMed    
     
     
     October 2021
139. TRAUNER M, Fuchs CD
     Novel therapeutic targets for cholestatic and fatty liver disease.
     Gut. 2021 Oct 6. pii: gutjnl-2021-324305. doi: 10.1136/gutjnl-2021-324305.
     PubMed     Abstract available
     
     
     
140. 
     Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
     Gut. 2021;70:e7.
     PubMed    
     
     
     
141. WEBER S, Hellmuth JC, Scherer C, Muenchhoff M, et al
     Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
     Gut. 2021;70:1925-1932.
     PubMed     Abstract available
     
     
     
142. LIU T, Tan J, Wu M, Fan W, et al
     High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells.
     Gut. 2021;70:1965-1977.
     PubMed     Abstract available
     
     
     
143. JUNG J, Loomba RR, Imajo K, Madamba E, et al
     MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
     Gut. 2021;70:1946-1953.
     PubMed     Abstract available
     
     
     
144. MANKA P, Baba HA, Wedemeyer H, Kahraman A, et al
     Diet-refractory NASH in an elderly woman.
     Gut. 2021;70:1924-1945.
     PubMed    
     
     
     September 2021
145. AN J, Kim HI, Oh B, Oh YJ, et al
     Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
     Gut. 2021 Sep 7. pii: gutjnl-2021-325844. doi: 10.1136/gutjnl-2021-325844.
     PubMed    
     
     
     
146. JACHS M, Hartl L, Schaufler D, Desbalmes C, et al
     Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
     Gut. 2021;70:1758-1767.
     PubMed     Abstract available
     
     
     August 2021
147. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
     Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
     Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
     PubMed     Abstract available
     
     
     
148. LIU J, Geng W, Sun H, Liu C, et al
     Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
     Gut. 2021 Aug 3. pii: gutjnl-2021-325189. doi: 10.1136/gutjnl-2021-325189.
     PubMed     Abstract available
     
     
     
149. HEINRICH B, Gertz EM, Schaffer AA, Craig A, et al
     The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.
     Gut. 2021 Aug 2. pii: gutjnl-2021-325288. doi: 10.1136/gutjnl-2021-325288.
     PubMed     Abstract available
     
     
     July 2021
150. SHENG J, Zhang J, Wang L, Tano V, et al
     Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
     Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
     PubMed     Abstract available
     
     
     
151. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
     Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
     Gut. 2021;70:1375-1382.
     PubMed     Abstract available
     
     
     
152. WRZOSEK L, Ciocan D, Hugot C, Spatz M, et al
     Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
     Gut. 2021;70:1299-1308.
     PubMed     Abstract available
     
     
     June 2021
153. PARK H, Yoon EL, Cho S, Jun DW, et al
     Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
     Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
     PubMed    
     
     
     
154. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
     Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
     Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.
     PubMed    
     
     
     May 2021
155. SUN J, Wu G, Pastor F, Rahman N, et al
     RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
     Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
     PubMed     Abstract available
     
     
     
156. ARMANDI A, Schattenberg JM
     NAFLD between genes and environment: what drives fibrogenesis?
     Gut. 2021;70:815-816.
     PubMed    
     
     
     
157. MANTOVANI A, Petracca G, Beatrice G, Tilg H, et al
     Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
     Gut. 2021;70:962-969.
     PubMed     Abstract available
     
     
     April 2021
158. XIE Z, Gao Y, Ho C, Li L, et al
     Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
     Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
     PubMed     Abstract available
     
     
     
159. WANG X, He Y, Mackowiak B, Gao B, et al
     MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
     Gut. 2021;70:784-795.
     PubMed     Abstract available
     
     
     
160. ZHANG X, Coker OO, Chu ES, Fu K, et al
     Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
     Gut. 2021;70:761-774.
     PubMed     Abstract available
     
     
     March 2021
161. GRANDER C, Schaefer B, Schwarzler J, Grabherr F, et al
     Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
     Gut. 2021;70:585-594.
     PubMed     Abstract available
     
     
     February 2021
162. CHEN HN, Shu Y, Liao F, Liao X, et al
     Genomic evolution and diverse models of systemic metastases in colorectal cancer.
     Gut. 2021 Feb 25. pii: gutjnl-2020-323703. doi: 10.1136/gutjnl-2020-323703.
     PubMed     Abstract available
     
     
     
163. GOESER F, Munch P, Lesker TR, Lutz PL, et al
     Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?
     Gut. 2021;70:438-440.
     PubMed    
     
     
     
164. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
     Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
     Gut. 2021;70:388-400.
     PubMed     Abstract available
     
     
     January 2021
165. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
     Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
     Gut. 2021;70:221-222.
     PubMed    
     
     
     
166. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
     Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
     Gut. 2021;70:219-221.
     PubMed    
     
     
     
167. TANAKA Y, Shimanaka Y, Caddeo A, Kubo T, et al
     LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.
     Gut. 2021;70:180-193.
     PubMed     Abstract available
     
     
     
168. HAGSTROM H, Thiele M, Roelstraete B, Soderling J, et al
     Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
     Gut. 2021;70:170-179.
     PubMed     Abstract available
     
     
     December 2020
169. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
     Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
     Gut. 2020;69:2193-2202.
     PubMed     Abstract available
     
     
     November 2020
170. FROST F, Kacprowski T, Ruhlemann M, Pietzner M, et al
     Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
     Gut. 2020 Nov 9. pii: gutjnl-2020-322753. doi: 10.1136/gutjnl-2020-322753.
     PubMed     Abstract available
     
     
     
171. LYU Z, Miao Q, Jiang P, Xiao X, et al
     Unexplained liver dysfunction in a young Chinese man with eosinophilia.
     Gut. 2020;69:1938-1987.
     PubMed    
     
     
     October 2020
172. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
     Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
     Gut. 2020;69:1855-1866.
     PubMed     Abstract available
     
     
     
173. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
     Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
     Gut. 2020;69:1787-1795.
     PubMed     Abstract available
     
     
     September 2020
174. TARGHER G, Byrne CD, Tilg H
     NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
     Gut. 2020;69:1691-1705.
     PubMed     Abstract available
     
     
     
175. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
     Duodenal and liver lesions in an adult with generalised weakness.
     Gut. 2020;69:1-2.
     PubMed    
     
     
     February 2020
176. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
     Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
     Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
     PubMed     Abstract available
     
     
     January 2020
177. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
     TGF-beta2 silencing to target biliary-derived liver diseases.
     Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.